As far as they know the Cubs don’t have any players linked to the Biogenesis scandal that led to the largest mass suspension in modern baseball history Monday.

But they haven’t escaped the ­impact.

The six-month battle Major League Baseball waged on players tied to the illegal Miami clinic in its larger war on performance-enhancing drugs has influenced how the Cubs do baseball business.

Think about the Cubs selecting college power hitter Kris Bryant over college power pitcher Jonathan Gray in the June draft. Think about the team signing international position players the last two years (Jorge Soler and Eloy Jimenez) and drafting a position player with its first pick last year (Albert Almora).

With offensive production down everywhere since baseball got relatively tough in its PED testing the truism that pitching pitching and more pitching is the key to championships is being challenged.

“It does make a big difference” Cubs general manager Jed Hoyer said. “As hard as it is to find really good pitching to find power in the game [today] is particularly difficult.

“I think for a bunch of years the biggest differences were power was easier to find and the aging curve got skewed.

“Long-term contracts were easier to sign because guys could maintain high levels into their 30s sometimes late-30s. It’s a young player’s game again.”